FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Gary Grover

Research Profile

Living Beings

Disorders

Chemicals & Drugs

Physiology

Anatomy

Procedures

Myocardial Reperfusion

Co-author Network

Publications

TOP 3
Alexandra A Nirschl; Yan Zou; Stanley R Krystek; James C Sutton; Ligaya M Simpkins; John A Lupisella; Joyce E Kuhns; Ramakrishna Seethala; Rajasree Golla; Paul G Sleph; Blake C Beehler; Gary J Grover; Donald Egan; Aberra Fura; Viral P Vyas; Yi-Xin Li; John S Sack; Kevin F Kish; Yongmi An; James A Bryson; Jack Z Gougoutas; John D DiMarco; Robert Zahler; Jacek Ostrowski; Lawrence G Hamann
N-aryl-oxazolidin-2-imine muscle selective androgen receptor modulators enhance potency through pharmacophore reorientation.
Galina Bryzgalova; Suad Effendic; Akhtar Khan; Stefan Rehnmark; Peter Barbounis; Jamie Boulet; Gao Dong; Rajni Singh; Sue Shapses; Johan Malm; Paul Webb; John D Baxter; Gary J Grover
Anti-obesity, anti-diabetic, and lipid lowering effects of the thyroid receptor beta subtype selective agonist KB-141.
James J Li; Haixia Wang; Jun Li; Fucheng Qu; Stephen G Swartz; Andrés S Hernández; Scott A Biller; Jeffrey A Robl; Joseph A Tino; Dorothy Slusarchyk; Ramakrishna Seethala; Paul G Sleph; Mujing Yan; Gary J Grover; Neil Flynn; Brian J Murphy; David Gordon
Tetrazole based amides as growth hormone secretagogues.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Gary Grover (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2009: Alexandra A Nirschl; Yan Zou; Stanley R Krystek; James C Sutton; Ligaya M Simpkins; John A Lupisella; Joyce E Kuhns; Ramakrishna Seethala; Rajasree Golla; Paul G Sleph; Blake C Beehler; Gary J Grover; Donald Egan; Aberra Fura; Viral P Vyas; Yi-Xin Li; John S Sack; Kevin F Kish; Yongmi An; James A Bryson; Jack Z Gougoutas; John D DiMarco; Robert Zahler; Jacek Ostrowski; Lawrence G Hamann
N-aryl-oxazolidin-2-imine muscle selective androgen receptor modulators enhance potency through pharmacophore reorientation.
Journal of medicinal chemistry 2009;52(9):2794-8.
2008: Galina Bryzgalova; Suad Effendic; Akhtar Khan; Stefan Rehnmark; Peter Barbounis; Jamie Boulet; Gao Dong; Rajni Singh; Sue Shapses; Johan Malm; Paul Webb; John D Baxter; Gary J Grover
Anti-obesity, anti-diabetic, and lipid lowering effects of the thyroid receptor beta subtype selective agonist KB-141.
The Journal of steroid biochemistry and molecular biology 2008;111(3-5):262-7.
2008: James J Li; Haixia Wang; Jun Li; Fucheng Qu; Stephen G Swartz; Andrés S Hernández; Scott A Biller; Jeffrey A Robl; Joseph A Tino; Dorothy Slusarchyk; Ramakrishna Seethala; Paul G Sleph; Mujing Yan; Gary J Grover; Neil Flynn; Brian J Murphy; David Gordon
Tetrazole based amides as growth hormone secretagogues.
Bioorganic & medicinal chemistry letters 2008;18(8):2536-9.
2008: Jun Li; Stephanie Y Chen; Shiwei Tao; Haixia Wang; James J Li; Steve Swartz; Christa Musial; Andres A Hernandez; Neil Flynn; Brian J Murphy; Blake Beehler; Kenneth E Dickinson; Leah Giupponi; Gary J Grover; Ramakrishna Seethala; Paul G Sleph; Dorothy Slusarchyk; Mujing Yan; William G Humphreys; Hongjian Zhang; William R Ewing; Jeffrey A Robl; David Gordon; Joseph A Tino
Design and synthesis of tetrazole-based growth hormone secretagogue: the SAR studies of the O-benzyl serine side chain.
Bioorganic & medicinal chemistry letters 2008;18(6):1825-9.
2008: Andrés S Hernández; Stephen G Swartz; Dorothy Slusarchyk; Mujing Yan; Ramakrishna Seethala; Paul G Sleph; Gary J Grover; Kenneth Dickinson; Leah Giupponi; Timothy W Harper; W Griffith Humphreys; Daniel A Longhi; Neil Flynn; Brian J Murphy; David A Gordon; Scott A Biller; Jeffrey A Robl; Joseph A Tino
Optimization of 1H-tetrazole-1-alkanenitriles as potent orally bioavailable growth hormone secretagogues.
Bioorganic & medicinal chemistry letters 2008;18(6):2067-72.
2007: Andrés S Hernández; Peter T Cheng; Christa M Musial; Stephen G Swartz; Rocco J George; Gary J Grover; Dorothy Slusarchyk; Ramakrishna Seethala; Mark Smith; Kenneth Dickinson; Leah Giupponi; Daniel A Longhi; Neil Flynn; Brian J Murphy; David A Gordon; Scott A Biller; Jeffrey A Robl; Joseph A Tino
Discovery, synthesis, and structure-activity studies of tetrazole based growth hormone secretagogues.
Bioorganic & medicinal chemistry letters 2007;17(21):5928-33.
2007: Mark C Manfredi; Yingzhi Bi; Alexandra A Nirschl; James C Sutton; Ramakrishna Seethala; Rajasree Golla; Blake C Beehler; Paul G Sleph; Gary J Grover; Jacek Ostrowski; Lawrence G Hamann
Synthesis and SAR of tetrahydropyrrolo[1,2-b][1,2,5]thiadiazol-2(3H)-one 1,1-dioxide analogues as highly potent selective androgen receptor modulators.
Bioorganic & medicinal chemistry letters 2007;17(16):4487-90.
2007: Neeraj Garg; Yi-Lin Li; Ana Maria Garcia Collazo; Chris Litten; Denis E Ryono; Minsheng Zhang; Yolanda Caringal; Robert P Brigance; Wei Meng; William N Washburn; Peter Agback; Karin Mellström; Stefan Rehnmark; Mahmoud Rahimi-Ghadim; Thomas Norin; Marlena Grynfarb; Johnny Sandberg; Gary J Grover; Johan Malm
Thyroid receptor ligands. Part 8: Thyromimetics derived from N-acylated-alpha-amino acid derivatives displaying modulated pharmacological selectivity compared with KB-141.
Bioorganic & medicinal chemistry letters 2007;17(15):4131-4.
2007: Gary J Grover; Celeste Dunn; Ngoc-Ha Nguyen; Jamie Boulet; Gao Dong; Jason Domogauer; Peter Barbounis; Thomas S Scanlan
Pharmacological profile of the thyroid hormone receptor antagonist NH3 in rats.
The Journal of pharmacology and experimental therapeutics 2007;322(1):385-90.
2007: James J Li; James C Sutton; Alexandra Nirschl; Yan Zou; Haixia Wang; Chongqing Sun; Zulan Pi; Rebecca Johnson; Stanley R Krystek; Ramakrishna Seethala; Rajasree Golla; Paul G Sleph; Blake C Beehler; Gary J Grover; Aberra Fura; Viral P Vyas; Cindy Y Li; Jack Z Gougoutas; Michael A Galella; Robert Zahler; Jacek Ostrowski; Lawrence G Hamann
Discovery of potent and muscle selective androgen receptor modulators through scaffold modifications.
Journal of medicinal chemistry 2007;50(13):3015-25.
2007: Pratik Devasthale; Sean Chen; Yoon Jeon; Fucheng Qu; Denis E Ryono; Wei Wang; Hao Zhang; Lin Cheng; Dennis Farrelly; Rajasree Golla; Gary J Grover; Zhengping Ma; Lisa Moore; Ramakrishna Seethala; Wei Sun; Arthur M Doweyko; Gamini Chandrasena; Paul G Sleph; Narayanan Hariharan; Peter T Cheng
Discovery of tertiary aminoacids as dual PPARalpha/gamma agonists-I.
Bioorganic & medicinal chemistry letters 2007;17(8):2312-6.
2007: Gary J Grover; Karin Mellström; Johan Malm
Therapeutic potential for thyroid hormone receptor-beta selective agonists for treating obesity, hyperlipidemia and diabetes.
Current vascular pharmacology 2007;5(2):141-54.
2007: Johan Malm; Gary J Grover; Mathias Färnegårdh
Recent advances in the development of agonists selective for beta1-type thyroid hormone receptor.
Mini reviews in medicinal chemistry 2007;7(1):79-86.
2007: Jacek Ostrowski; Joyce E Kuhns; John A Lupisella; Mark C Manfredi; Blake C Beehler; Stanley R Krystek; Yingzhi Bi; Chongqing Sun; Ramakrishna Seethala; Rajasree Golla; Paul G Sleph; Aberra Fura; Yongmi An; Kevin Kish; John S Sack; Kasim A Mookhtiar; Gary J Grover; Lawrence G Hamann
Pharmacological and x-ray structural characterization of a novel selective androgen receptor modulator: potent hyperanabolic stimulation of skeletal muscle with hypostimulation of prostate in rats.
Endocrinology 2007;148(1):4-12.
2006: Chongqing Sun; Jeffrey A Robl; Tammy C Wang; Yanting Huang; Joyce E Kuhns; John A Lupisella; Blake C Beehler; Rajasree Golla; Paul G Sleph; Ramakrishna Seethala; Aberra Fura; Stanley R Krystek; Yongmi An; Mary F Malley; John S Sack; Mark E Salvati; Gary J Grover; Jacek Ostrowski; Lawrence G Hamann
Discovery of potent, orally-active, and muscle-selective androgen receptor modulators based on an N-aryl-hydroxybicyclohydantoin scaffold.
Journal of medicinal chemistry 2006;49(26):7596-9.
2006: Koehler F Konrad; Sandra Gordon; Peter Brandt; Bo Carlsson; Anna Bäcksbro-Saeidi; Theresa Apelqvist; Peter Agback; Gary J Grover; William Nelson; Marlena Grynfarb; Mathias Färnegårdh; Stefan Rehnmark; Johan Malm
Thyroid receptor ligands. 6. A high affinity "direct antagonist" selective for the thyroid hormone receptor.
Journal of medicinal chemistry 2006;49(23):6635-7.
2006: Blake C Beehler; Paul G Sleph; Latifa Benmassaoud; Gary J Grover
Reduction of skeletal muscle atrophy by a proteasome inhibitor in a rat model of denervation.
Experimental biology and medicine (Maywood, N.J.) 2006;231(3):335-41.
2005: James J Li; Haixia Wang; Fucheng Qu; Christa Musial; Joseph A Tino; Jeffrey A Robl; Dorothy Slusarchyk; Rajasree Golla; Ramakrishna Seethala; Kenneth Dickinson; Leah Giupponi; Gary J Grover; Paul G Sleph; Neil Flynn; Brian J Murphy; David Gordon; Melissa Kung; Robert Stoffel
Tetrahydroisoquinoline 1-carboxamides as growth hormone secretagogues.
Bioorganic & medicinal chemistry letters 2005;15(7):1799-802.
2004: Gary J Grover; Karnail S Atwal; Paul G Sleph; Feng-Li Wang; Hossain Monshizadegan; Thomas Monticello; David Green
Excessive ATP hydrolysis in ischemic myocardium by mitochondrial F1F0-ATPase: effect of selective pharmacological inhibition of mitochondrial ATPase hydrolase activity.
American journal of physiology. Heart and circulatory physiology 2004;287(4):H1747-55.
2004: Gary J Grover; Donald M Egan; Paul G Sleph; Blake C Beehler; Grazia Chiellini; Ngoc-Ha Nguyen; John D Baxter; Thomas S Scanlan
Effects of the thyroid hormone receptor agonist GC-1 on metabolic rate and cholesterol in rats and primates: selective actions relative to 3,5,3'-triiodo-L-thyronine.
Endocrinology 2004;145(4):1656-61.
2004: Karnail S Atwal; Paulina Wang; W Lynn Rogers; Paul G Sleph; Hossain Monshizadegan; Francis N Ferrara; Sarah C Traeger; David Green; Gary J Grover
Small molecule mitochondrial F1F0 ATPase hydrolase inhibitors as cardioprotective agents. Identification of 4-(N-arylimidazole)-substituted benzopyran derivatives as selective hydrolase inhibitors.
Journal of medicinal chemistry 2004;47(5):1081-4.
2003: Gary J Grover; Dennis E Burkett; Charles S Parham; Robert J Scalese; Kenneth K Sadanaga
Protective effect of mitochondrial KATP activation in an isolated gracilis model of ischemia and reperfusion in dogs.
Journal of cardiovascular pharmacology 2003;42(6):790-2.
2003: Olaf Oldenburg; Xi-Ming Yang; Thomas Krieg; Keith D Garlid; Michael V Cohen; Gary J Grover; James M Downey
P1075 opens mitochondrial K(ATP) channels and generates reactive oxygen species resulting in cardioprotection of rabbit hearts.
Journal of molecular and cellular cardiology 2003;35(9):1035-42.
2003: Gary J Grover; Karin Mellström; Liu Ye; Johan Malm; Yi-Lin Li; Lars-Göran Bladh; Paul G Sleph; Mark A Smith; Rocco George; Björn Vennström; Kasim A Mookhtiar; Ryan Horvath; Jessica Speelman; Donald Egan; John D Baxter
Selective thyroid hormone receptor-beta activation: a strategy for reduction of weight, cholesterol, and lipoprotein (a) with reduced cardiovascular liability.
Proceedings of the National Academy of Sciences of the United States of America 2003;100(17):10067-72.
2003: Eric R Gross; Jason N Peart; Anna K Hsu; Gary J Grover; Garrett J Gross
K(ATP) opener-induced delayed cardioprotection: involvement of sarcolemmal and mitochondrial K(ATP) channels, free radicals and MEK1/2.
Journal of molecular and cellular cardiology 2003;35(8):985-92.
2003: Liu Ye; Yi-Lin Li; Karin Mellström; Charlotta Mellin; Lars-Göran Bladh; Koehler F Konrad; Neeraj Garg; Ana Maria Garcia Collazo; Chris Litten; Bolette Husman; Karina Persson; Jan Ljunggren; Gary J Grover; Paul G Sleph; Rocco George; Johan Malm
Thyroid receptor ligands. 1. Agonist ligands selective for the thyroid receptor beta1.
Journal of medicinal chemistry 2003;46(9):1580-8.
2002: Gary J Grover; Albert J D'Alonzo; Raymond B Darbenzio; Charles S Parham; Thomas A Hess; Mohinder S Bathala
In vivo characterization of the mitochondrial selective K(ATP) opener (3R)-trans-4-((4-chlorophenyl)-N-(1H-imidazol-2-ylmethyl)dimethyl-2H-1-benzopyran-6-carbonitril monohydrochloride (BMS-191095): cardioprotective, hemodynamic, and electrophysiological effects.
The Journal of pharmacology and experimental therapeutics 2002;303(1):132-40.
2002: Gary J Grover; Karnail S Atwal
Pharmacologic profile of the selective mitochondrial-K(ATP) opener BMS-191095 for treatment of acute myocardial ischemia.
Cardiovascular drug reviews 2002;20(2):121-36.
2001: Gary J Grover; Albert J D'Alonzo; Keith D Garlid; R Bajgar; Nicholas J Lodge; Paul G Sleph; Raymond B Darbenzio; T A Hess; M A Smith; Petr Paucek; Karnail S Atwal
Pharmacologic characterization of BMS-191095, a mitochondrial K(ATP) opener with no peripheral vasodilator or cardiac action potential shortening activity.
The Journal of pharmacology and experimental therapeutics 2001;297(3):1184-92.
2000: Susanne U Trost; Eric Swanson; Bernd Gloss; D B Wang-Iverson; H Zhang; T Volodarsky; Gary J Grover; John D Baxter; Grazia Chiellini; Thomas S Scanlan; Wolfgang H Dillmann
The thyroid hormone receptor-beta-selective agonist GC-1 differentially affects plasma lipids and cardiac activity.
Endocrinology 2000;141(9):3057-64.
2000: Gary J Grover; Keith D Garlid
ATP-Sensitive potassium channels: a review of their cardioprotective pharmacology.
Journal of molecular and cellular cardiology 2000;32(4):677-95.
1999: Charles Z Ding; George Rovnyak; Raj Misra; Gary J Grover; Arthur V Miller; Syed Z Ahmed; YF Kelly; Diane E Normandin; Paul G Sleph; Karnail S Atwal
Cardioselective antiischemic ATP-sensitive potassium channel (K(ATP)) openers. 6. Effect of modifications at C6 of benzopyranyl cyanoguanidines.
Journal of medicinal chemistry 1999;42(18):3711-7.
1998: Albert J D'Alonzo; J L Zhu; Raymond B Darbenzio; Charles R Dorso; Gary J Grover
Proarrhythmic effects of pinacidil are partially mediated through enhancement of catecholamine release in isolated perfused guinea-pig hearts.
Journal of molecular and cellular cardiology 1998;30(2):415-23.
1998: Karnail S Atwal; Gary J Grover; Nicholas J Lodge; Diane E Normandin; Sarah C Traeger; Paul G Sleph; RB Cohen; CC Bryson; Kenneth Dickinson
Binding of ATP-sensitive potassium channel (KATP) openers to cardiac membranes: correlation of binding affinities with cardioprotective and smooth muscle relaxing potencies.
Journal of medicinal chemistry 1998;41(3):271-5.
1998: David Green; H N Murray; Paul G Sleph; Feng-Li Wang; AJ Baird; W Lynn Rogers; Gary J Grover
Preconditioning in rat hearts is independent of mitochondrial F1F0 ATPase inhibition.
The American journal of physiology 1998;274(1 Pt 2):H90-7.
1997: Keith D Garlid; Petr Paucek; V Yarov-Yarovoy; H N Murray; Raymond B Darbenzio; Albert J D'Alonzo; Nicholas J Lodge; M A Smith; Gary J Grover
Cardioprotective effect of diazoxide and its interaction with mitochondrial ATP-sensitive K+ channels. Possible mechanism of cardioprotection.
Circulation research 1997;81(6):1072-82.
1997: Gary J Grover
Pharmacology of ATP-sensitive potassium channel (KATP) openers in models of myocardial ischemia and reperfusion.
Canadian journal of physiology and pharmacology 1997;75(4):309-15.
1997: A W Gomoll; R A Roth; R E Swillo; AJ Baird; C S Sargent; R W Behling; H J Malone; Gary J Grover
Effect of timing of treatment of the glyburide-reversible cardioprotective activity of BMS-180448.
The Journal of pharmacology and experimental therapeutics 1997;281(1):24-33.
1997: Garrett J Gross; David A Mei; Paul G Sleph; Gary J Grover
Adenosine A1 receptor blockade does not abolish the cardioprotective effects of the adenosine triphosphate-sensitive potassium channel opener bimakalim.
The Journal of pharmacology and experimental therapeutics 1997;280(2):533-40.
1997: George Rovnyak; Syed Z Ahmed; Charles Z Ding; S Dzwonczyk; Francis N Ferrara; W G Humphreys; Gary J Grover; D Santafianos; Karnail S Atwal; AJ Baird; L G McLaughlin; Diane E Normandin; Paul G Sleph; Sarah C Traeger
Cardioselective antiischemic ATP-sensitive potassium channel (KATP) openers. 5. Identification of 4-(N-aryl)-substituted benzopyran derivatives with high selectivity.
Journal of medicinal chemistry 1997;40(1):24-34.
1997: Gary J Grover; Paul G Sleph; S Dzwonczyk; H J Malone; R W Behling
Glyburide-reversible cardioprotective effects of BMS-180448: functional and energetic considerations.
Journal of cardiovascular pharmacology 1997;29(1):28-38.
1996: Gary J Grover; Albert J D'Alonzo; S Dzwonczyk; C S Parham; Raymond B Darbenzio
Preconditioning is not abolished by the delayed rectifier K+ blocker dofetilide.
The American journal of physiology 1996;271(3 Pt 2):H1207-14.
1996: O Vesterqvist; C A Sargent; Gary J Grover; Martin Ogletree
Myocardial calcium-independent phospholipase A2 activity during global ischemia in isolated rabbit hearts.
Cardiovascular research 1996;31(6):932-40.
1996: Gary J Grover; A J Baird; Paul G Sleph
Lack of a pharmacologic interaction between ATP-sensitive potassium channels and adenosine A1 receptors in ischemic rat hearts.
Cardiovascular research 1996;31(4):511-7.
1996: Albert J D'Alonzo; Gary J Grover; Raymond B Darbenzio; J C Sewter; T A Hess; S Dzwonczyk; Paul G Sleph
Hemodynamic and cardiac effects of BMS-180448, a novel K+ATP opener, in anesthetized dogs and isolated rat hearts.
Pharmacology 1996;52(2):101-12.
1996: C A Sargent; M W Wilde; S Dzwonczyk; J G Tuttle; H N Murray; Karnail S Atwal; Gary J Grover
Glyburide-reversible cardioprotective effects of calcium-independent phospholipase A2 inhibition in ischemic rat hearts.
Cardiovascular research 1996;31(2):270-7.
1996: Gary J Grover; C S Parham; D B Whigan; J G Mitroka
BMS-180448, a novel glyburide-reversible cardioprotective agent, enhances postischemic recovery of contractile function in dogs.
The Journal of pharmacology and experimental therapeutics 1996;276(2):380-7.
1996: Karnail S Atwal; F N Ferrara; Charles Z Ding; Gary J Grover; Paul G Sleph; S Dzwonczyk; A J Baird; Diane E Normandin
Cardioselective antiischemic ATP-sensitive potassium channel openers. 4. Structure-activity studies on benzopyranylcyanoguanidines: replacement of the benzopyran portion.
Journal of medicinal chemistry 1996;39(1):304-13.
1996: Gary J Grover
The role of ATP-sensitive potassium channels in myocardial ischemia: pharmacology and implications for the future.
EXS 1996;76():313-24.
1996: Gary J Grover; S Dzwonczyk; T M Monticello
Comparative cardioprotective effects of cromakalim and diltiazem in ischemic hypertrophied rat hearts.
The American journal of physiology 1996;270(1 Pt 2):H174-82.
1995: Albert J D'Alonzo; Raymond B Darbenzio; J C Sewter; T A Hess; Gary J Grover; Paul G Sleph; Diane E Normandin; Nicholas J Lodge
A comparison between the effects of BMS-180448, a novel K+ channel opener, and cromakalim in rat and dog.
European journal of pharmacology 1995;294(1):271-80.
1995: Gary J Grover; Paul G Sleph
Protective effect of K(ATP) openers in ischemic rat hearts treated with a potassium cardioplegic solution.
Journal of cardiovascular pharmacology 1995;26(5):698-706.
1995: Gary J Grover; Albert J D'Alonzo; T Hess; Paul G Sleph; Raymond B Darbenzio
Glyburide-reversible cardioprotective effect of BMS-180448 is independent of action potential shortening.
Cardiovascular research 1995;30(5):731-8.
1995: Karnail S Atwal; Gary J Grover; S Z Ahmed; Paul G Sleph; S Dzwonczyk; A J Baird; Diane E Normandin
Cardioselective anti-ischemic ATP-sensitive potassium channel openers. 3. Structure-activity studies on benzopyranyl cyanoguanidines: modification of the cyanoguanidine portion.
Journal of medicinal chemistry 1995;38(17):3236-45.
1995: Gary J Grover; S Dzwonczyk; D M McMullen; Diane E Normandin; C S Parham; Paul G Sleph; S Moreland
Pharmacologic profile of the dihydropyrimidine calcium channel blockers SQ 32,547 and SQ 32,926 [correction of SQ 32,946].
Journal of cardiovascular pharmacology 1995;26(2):289-94.
1995: Gary J Grover; Albert J D'Alonzo; C S Parham; Raymond B Darbenzio
Cardioprotection with the KATP opener cromakalim is not correlated with ischemic myocardial action potential duration.
Journal of cardiovascular pharmacology 1995;26(1):145-52.
1995: Karnail S Atwal; Gary J Grover; F N Ferrara; S Z Ahmed; Paul G Sleph; S Dzwonczyk; Diane E Normandin
Cardioselective antiischemic ATP-sensitive potassium channel openers. 2. Structure-activity studies on benzopyranylcyanoguanidines: modification of the benzopyran ring.
Journal of medicinal chemistry 1995;38(11):1966-73.
1995: Gary J Grover; C S Parham; S Youssef; Martin Ogletree
Protective effect of the serotonin receptor antagonist cinanserin in two canine models of pacing-induced myocardial ischemia.
Pharmacology 1995;50(5):286-97.
1995: Gary J Grover; H N Murray; A J Baird; S Dzwonczyk
The KATP blocker sodium 5-hydroxydecanoate does not abolish preconditioning in isolated rat hearts.
European journal of pharmacology 1995;277(2-3):271-4.
1995: Albert J D'Alonzo; Gary J Grover; Raymond B Darbenzio; T A Hess; Paul G Sleph; S Dzwonczyk; J L Zhu; J C Sewter
In vitro effects of capsaicin: antiarrhythmic and antiischemic activity.
European journal of pharmacology 1995;272(2-3):269-78.
1995: E O Weselcouch; A J Baird; Paul G Sleph; S Dzwonczyk; H N Murray; Gary J Grover
Endogenous catecholamines are not necessary for ischaemic preconditioning in the isolated perfused rat heart.
Cardiovascular research 1995;29(1):126-32.
1995: Gary J Grover; John McCullough; Albert J D'Alonzo; C A Sargent; Karnail S Atwal
Cardioprotective profile of the cardiac-selective ATP-sensitive potassium channel opener BMS-180448.
Journal of cardiovascular pharmacology 1995;25(1):40-50.
1995: E O Weselcouch; A J Baird; Paul G Sleph; Gary J Grover
Inhibition of nitric oxide synthesis does not affect ischemic preconditioning in isolated perfused rat hearts.
The American journal of physiology 1995;268(1 Pt 2):H242-9.
1994: A W Gomoll; Gary J Grover; M L Ogletree
Myocardial salvage efficacy of the thromboxane receptor antagonist ifetroban in ferrets and dogs.
Journal of cardiovascular pharmacology 1994;24(6):960-8.
1994: C A Sargent; S Dzwonczyk; Paul G Sleph; M Wilde; Gary J Grover
Pyruvate increases threshold for preconditioning in globally ischemic rat hearts.
The American journal of physiology 1994;267(4 Pt 2):H1403-9.
1994: Gary J Grover; W A Schumacher; M L Ogletree
Thromboxane receptor antagonist BMS-180291, but not aspirin, reduces the severity of pacing-induced ischemia in dogs.
Journal of cardiovascular pharmacology 1994;24(3):493-9.
1994: C A Sargent; S Dzwonczyk; Gary J Grover
The effect of alpha 2-adrenoceptor antagonists in isolated globally ischemic rat hearts.
European journal of pharmacology 1994;261(1-2):25-32.
1994: Albert J D'Alonzo; Raymond B Darbenzio; T A Hess; J C Sewter; Paul G Sleph; Gary J Grover
Effect of potassium on the action of the KATP modulators cromakalim, pinacidil, or glibenclamide on arrhythmias in isolated perfused rat heart subjected to regional ischaemia.
Cardiovascular research 1994;28(6):881-7.
1994: Gary J Grover
Protective effects of ATP sensitive potassium channel openers in models of myocardial ischaemia.
Cardiovascular research 1994;28(6):778-82.
1994: Gary J Grover; Albert J D'Alonzo; Paul G Sleph; S Dzwonczyk; T A Hess; Raymond B Darbenzio
The cardioprotective and electrophysiological effects of cromakalim are attenuated by meclofenamate through a cyclooxygenase-independent mechanism.
The Journal of pharmacology and experimental therapeutics 1994;269(2):536-40.
1994: O Vesterqvist; C A Sargent; Gary J Grover; B M Warrack; G C DiDonato; Martin Ogletree
Characterization of rabbit myocardial phospholipase A2 activity using endogenous phospholipid substrates.
Analytical biochemistry 1994;217(2):210-9.
1994: Gary J Grover; Paul G Sleph
The cardioprotective effects of R 75231 and lidoflazine are not caused by adenosine A1 receptor activation.
The Journal of pharmacology and experimental therapeutics 1994;268(1):90-6.
1994: Gary J Grover
Protective effects of ATP-sensitive potassium-channel openers in experimental myocardial ischemia.
Journal of cardiovascular pharmacology 1994;24 Suppl 4():S18-27.
1993: Karnail S Atwal; Gary J Grover; S Z Ahmed; F N Ferrara; T W Harper; K S Kim; Paul G Sleph; S Dzwonczyk; A D Russell; S Moreland
Cardioselective anti-ischemic ATP-sensitive potassium channel openers.
Journal of medicinal chemistry 1993;36(24):3971-4.
1993: Gary J Grover; Paul G Sleph; S Dzwonczyk; John McCullough
Cardioprotective effects of a novel calcium antagonist related to the structure of cromakalim.
The Journal of pharmacology and experimental therapeutics 1993;267(1):102-7.
1993: Gary J Grover; C A Sargent; S Dzwonczyk; Diane E Normandin; M J Antonaccio
Protective effect of serotonin (5-HT2) receptor antagonists in ischemic rat hearts.
Journal of cardiovascular pharmacology 1993;22(4):664-72.
1993: C A Sargent; Paul G Sleph; S Dzwonczyk; Diane E Normandin; M J Antonaccio; Gary J Grover
Cardioprotective effects of the cyanoguanidine potassium channel opener P-1075.
Journal of cardiovascular pharmacology 1993;22(4):564-70.
1993: C A Sargent; Gary J Grover; M J Antonaccio; John McCullough
The cardioprotective, vasorelaxant and electrophysiological profile of the large conductance calcium-activated potassium channel opener NS-004.
The Journal of pharmacology and experimental therapeutics 1993;266(3):1422-9.
1993: Gary J Grover; S Dzwonczyk; C S Parham
The endothelin-1 receptor antagonist BQ-123 reduces infarct size in a canine model of coronary occlusion and reperfusion.
Cardiovascular research 1993;27(9):1613-8.
1993: Gary J Grover
An explanation for the reported observation that ATP dependent potassium channel openers fail to mimic preconditioning.
Cardiovascular research 1993;27(9):1564.
1993: C A Sargent; O Vesterqvist; M L Ogletree; Gary J Grover
Effects of endogenous and exogenous lysophosphatidylcholine in isolated perfused rat hearts.
Journal of molecular and cellular cardiology 1993;25(8):905-13.
1993: C A Sargent; Paul G Sleph; S Dzwonczyk; M A Smith; Diane E Normandin; M J Antonaccio; Gary J Grover
Cardioprotection in ischemic rat hearts with the SH-containing angiotensin-converting enzyme inhibitor zofenopril: possible involvement of the ATP-sensitive potassium channel.
The Journal of pharmacology and experimental therapeutics 1993;265(2):609-18.
1993: Gary J Grover; S Dzwonczyk; Paul G Sleph; C A Sargent
The ATP-sensitive potassium channel blocker glibenclamide (glyburide) does not abolish preconditioning in isolated ischemic rat hearts.
The Journal of pharmacology and experimental therapeutics 1993;265(2):559-64.
1992: Gary J Grover; Paul G Sleph; M Fox; NC Trippodo
Role of endothelin-1 and big endothelin-1 in modulating coronary vascular tone, contractile function and severity of ischemia in rat hearts.
The Journal of pharmacology and experimental therapeutics 1992;263(3):1074-82.
1992: Albert J D'Alonzo; Raymond B Darbenzio; C S Parham; Gary J Grover
Effects of intracoronary cromakalim on postischaemic contractile function and action potential duration.
Cardiovascular research 1992;26(11):1046-53.
1992: Gary J Grover; Paul G Sleph; S Dzwonczyk
Role of myocardial ATP-sensitive potassium channels in mediating preconditioning in the dog heart and their possible interaction with adenosine A1-receptors.
Circulation 1992;86(4):1310-6.
1992: C A Sargent; O Vesterqvist; John McCullough; Martin Ogletree; Gary J Grover
Effect of the phospholipase A2 inhibitors quinacrine and 7,7-dimethyleicosadienoic acid in isolated globally ischemic rat hearts.
The Journal of pharmacology and experimental therapeutics 1992;262(3):1161-7.
1992: C A Sargent; Paul G Sleph; S Dzwonczyk; M A Smith; Gary J Grover
Effect of calmodulin and protein kinase C inhibitors on globally ischemic rat hearts.
Journal of cardiovascular pharmacology 1992;20(2):251-60.
1992: O Vesterqvist; C A Sargent; S C Taylor; J Newburger; A A Tymiak; Gary J Grover; Martin Ogletree
Quantitation of lysophosphatidylcholine molecular species in rat cardiac tissue.
Analytical biochemistry 1992;204(1):72-8.
1992: Franklin Clayton; T A Hess; M A Smith; Gary J Grover
Coronary reactive hyperemia and adenosine-induced vasodilation are mediated partially by a glyburide-sensitive mechanism.
Pharmacology 1992;44(2):92-100.
1992: C A Sargent; S Dzwonczyk; Gary J Grover
Effect of the potassium channel opener EMD 56431 on globally ischemic rat hearts.
Pharmacology 1992;45(5):260-8.
1991: John McCullough; Diane E Normandin; M L Conder; Paul G Sleph; S Dzwonczyk; Gary J Grover
Specific block of the anti-ischemic actions of cromakalim by sodium 5-hydroxydecanoate.
Circulation research 1991;69(4):949-58.
1991: C A Sargent; M A Smith; S Dzwonczyk; Paul G Sleph; Gary J Grover
Effect of potassium channel blockade on the anti-ischemic actions of mechanistically diverse agents.
The Journal of pharmacology and experimental therapeutics 1991;259(1):97-103.
1991: Gary J Grover; Paul G Sleph; S Dzwonczyk; P Wang; W Fung; D Tobias; D W Cushman
Effects of different angiotensin-converting enzyme (ACE) inhibitors on ischemic isolated rat hearts: relationship between cardiac ACE inhibition and cardioprotection.
The Journal of pharmacology and experimental therapeutics 1991;257(3):919-29.
1991: Gary J Grover; J Newburger; Paul G Sleph; S Dzwonczyk; S C Taylor; S Z Ahmed; Karnail S Atwal
Cardioprotective effects of the potassium channel opener cromakalim: stereoselectivity and effects on myocardial adenine nucleotides.
The Journal of pharmacology and experimental therapeutics 1991;257(1):156-62.
1991: Gary J Grover; C S Parham; W A Schumacher
The cardioprotective effects of the thromboxane receptor antagonist SQ 30,741 are not reversed by aspirin.
Basic research in cardiology 1991;86(2):99-106.
1991: Gary J Grover; C S Parham; W A Schumacher
The combined antiischemic effects of the thromboxane receptor antagonist SQ 30,741 and tissue-type plasminogen activator.
American heart journal 1991;121(2 Pt 1):426-33.
1990: Gary J Grover; Paul G Sleph; S Dzwonczyk
Pharmacologic profile of cromakalim in the treatment of myocardial ischemia in isolated rat hearts and anesthetized dogs.
Journal of cardiovascular pharmacology 1990;16(6):853-64.
1990: Gary J Grover; S Dzwonczyk; Paul G Sleph
Reduction of ischemic damage in isolated rat hearts by the potassium channel opener, RP 52891.
European journal of pharmacology 1990;191(1):11-8.
1990: Gary J Grover; S Dzwonczyk; Paul G Sleph
Ruthenium red improves postischemic contractile function in isolated rat hearts.
Journal of cardiovascular pharmacology 1990;16(5):783-9.
1990: S Moreland; L M Antes; D M McMullen; Paul G Sleph; Gary J Grover
Myosin light-chain phosphorylation and vascular resistance in canine anterior tibial arteries in situ.
Pflügers Archiv : European journal of physiology 1990;417(2):180-4.
1990: Gary J Grover; Paul G Sleph; C S Parham; R J Brittain; J Krapcho; S Moreland
Anti-ischemic activity of the novel benzazepine calcium antagonist SQ 31,486.
Journal of cardiovascular pharmacology 1990;16(2):219-27.
1990: Gary J Grover; Paul G Sleph; H R Weiss
Effect of thromboxane receptor blockade on oxygen supply/consumption variables during reperfusion in the anesthetized dog.
The Journal of pharmacology and experimental therapeutics 1990;253(3):1097-102.
1990: Gary J Grover; Paul G Sleph; C S Parham
Nicorandil improves postischemic contractile function independently of direct myocardial effects.
Journal of cardiovascular pharmacology 1990;15(5):698-705.
1990: Gary J Grover; S Dzwonczyk; C S Parham; Paul G Sleph
The protective effects of cromakalim and pinacidil on reperfusion function and infarct size in isolated perfused rat hearts and anesthetized dogs.
Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy 1990;4(2):465-74.
1990: W A Schumacher; Gary J Grover
The thromboxane receptor antagonist SQ 30,741 reduces myocardial infarct size in monkeys when given during reperfusion at a threshold dose for improving reflow during thrombolysis.
Journal of the American College of Cardiology 1990;15(4):883-9.
1990: Gary J Grover; S Dzwonczyk; Paul G Sleph
Comparative anti-ischemic effects of dihydropyridine calcium antagonists in isolated perfused rat hearts: relationship of cardiodepression and cardioprotection.
Pharmacology 1990;40(3):137-49.
1990: Gary J Grover; A Hedberg; M L Ogletree
Direct myocardial effects of the thromboxane A2/prostaglandin H2 agonists U-46619 and SQ 26,655 under ischemic and nonischemic conditions.
Pharmacology 1990;41(1):1-15.
1989: Gary J Grover; C S Parham; Paul G Sleph; S Moreland
Anti-ischemic and vasorelaxant effects of the new benzazepine calcium channel blocker SQ 31,765.
The Journal of pharmacology and experimental therapeutics 1989;251(3):1020-5.
1989: Gary J Grover
Thromboxane receptor blockade with SQ 30,741 improves post-ischemic myocardial function in anesthetized dogs.
Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.) 1989;192(1):56-60.
1989: Gary J Grover; John McCullough; D E Henry; M L Conder; Paul G Sleph
Anti-ischemic effects of the potassium channel activators pinacidil and cromakalim and the reversal of these effects with the potassium channel blocker glyburide.
The Journal of pharmacology and experimental therapeutics 1989;251(1):98-104.
1989: Gary J Grover; Paul G Sleph
Dissociation of cardiodepression from cardioprotection with calcium antagonists: diltiazem protects ischemic rat myocardium with a lower functional cost as compared with verapamil or nifedipine.
Journal of cardiovascular pharmacology 1989;14(2):331-40.
1989: Gary J Grover; C S Parham
Role of thromboxane A2 in the control of myocardial O2 supply/consumption balance and severity of ischemia during pacing-induced ischemia.
Circulation research 1989;64(3):575-82.
1989: Gary J Grover; W A Schumacher
Effect of the thromboxane A2 receptor antagonist SQ 30,741 on ultimate myocardial infarct size, reperfusion injury and coronary flow reserve.
The Journal of pharmacology and experimental therapeutics 1989;248(2):484-91.
1989: D W Cushman; F L Wang; W C Fung; Gary J Grover; C M Harvey; R J Scalese; S L Mitch; J M DeForrest
Comparisons in vitro, ex vivo, and in vivo of the actions of seven structurally diverse inhibitors of angiotensin converting enzyme (ACE).
British journal of clinical pharmacology 1989;28 Suppl 2():115S-130S; discussion 130S-131S.
1989: Gary J Grover; W A Schumacher
The effect of the thromboxane A2 receptor antagonist SQ 29,548 on the severity of pacing-induced ischemia.
Basic research in cardiology 1989;84(1):103-10.
1988: Gary J Grover; W A Schumacher; M Simon; C Parham
The effect of the thromboxane A2/prostaglandin endoperoxide receptor antagonist SQ 30,741 on myocardial infarct size and blood flow during myocardial ischemia and reperfusion.
Journal of cardiovascular pharmacology 1988;12(6):701-9.
1988: Gary J Grover; I E Fulmor
Thromboxane A2 antagonist and diltiazem-induced enhancement of contractile function: the effect of timing of treatment.
The Journal of pharmacology and experimental therapeutics 1988;247(2):445-52.
1988: Gary J Grover; Paul G Sleph; C Parham
The role of thromboxane A2 in reperfusion injury.
Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.) 1988;188(4):504-8.
1988: Gary J Grover; Paul G Sleph; C S Parham
Effect of diltiazem on infarct size, reperfusion flow and flow reserve: the effect of timing of treatment.
The Journal of pharmacology and experimental therapeutics 1988;246(1):263-9.
1988: Gary J Grover; W A Schumacher
Effect of the thromboxane receptor antagonist SQ 29,548 on myocardial infarct size in dogs.
Journal of cardiovascular pharmacology 1988;11(1):29-35.
1987: Gary J Grover; C S Parham
The effect of diltiazem on ST-segment elevation and myocardial blood flow distribution during pacing-induced ischemia.
European journal of pharmacology 1987;143(1):109-17.
1987: Gary J Grover; C S Parham
Effect of intracoronary diltiazem on ST-segment elevation and myocardial blood flow during pacing-induced ischemia.
Journal of cardiovascular pharmacology 1987;10(5):548-54.